Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gemifloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | DPP4 | P27487 | 6/20 | 0.93 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.93 |
| ▸ | DRD1 | P21728 | 1/20 | 0.93 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | XBP1 | P17861 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | ATP6V1B2 | P21281 | 1/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gemifloxacin SCHEMBL136827 | 1.00 | LMNA (1.00) | LMNAKDM4EHSD17B10ABCC4DPP4 | |
| Gemifloxacin SCHEMBL3141327 | 1.00 | LMNA (1.00) | LMNAKDM4EHSD17B10ABCC4DPP4 | |
| Gemifloxacin SCHEMBL1237121 | 1.00 | LMNA (1.00) | LMNAKDM4EHSD17B10ABCC4DPP4 | |
| Gemifloxacin SCHEMBL29408809 | 1.00 | LMNA (1.00) | LMNAKDM4EHSD17B10ABCC4DPP4 | |
| Gemifloxacin SCHEMBL2421087 | 1.00 | LMNA (1.00) | LMNAKDM4EHSD17B10ABCC4DPP4 | |
| Gemifloxacin SCHEMBL5661711 | 0.99 | LMNA (0.98) | LMNAKDM4EHSD17B10ABCC4DPP4 | |
| Gemifloxacin SCHEMBL5661708 | 0.99 | LMNA (0.98) | LMNAKDM4EHSD17B10ABCC4DPP4 | |
| Gemifloxacin SCHEMBL3281156 | 0.99 | LMNA (0.98) | LMNAKDM4EHSD17B10ABCC4DPP4 | |
| Gemifloxacin SCHEMBL3281159 | 0.99 | LMNA (0.98) | LMNAKDM4EHSD17B10ABCC4DPP4 | |
| Gemifloxacin SCHEMBL5658681 | 0.99 | LMNA (0.98) | LMNAKDM4EHSD17B10ABCC4DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170253588-A1 | SALT OF NAPHTHYRIDINE CARBOXYLIC ACID DERIVATIVE | LG LIFE SCIENCES, LTD. (KR) | 2017-09-07 | — | — | US | claimed |
| US-20160264569-A1 | SALT OF NAPHTHYRIDINE CARBOXYLIC ACID DERIVATIVE | LG LIFE SCIENCES, LTD. (KR) | 2016-09-15 | — | — | US | claimed |
| US-20150291585-A1 | SALT OF NAPHTHYRIDINE CARBOXYLIC ACID DERIVATIVE | LG Life Sciences, Ltd (KR) | 2015-10-15 | — | — | US | claimed |
| US-20140187576-A1 | SALT OF NAPHTHYRIDINE CARBOXYLIC ACID DERIVATIVE | KIM AE RI (US) | 2014-07-03 | — | — | US | claimed |
| US-20130065917-A1 | SALT OF NAPHTHYRIDINE CARBOXYLIC ACID DERIVATIVE | LG CHEMICAL LTD. | 2013-03-14 | — | — | US | claimed |
| US-20110312987-A1 | SALT OF NAPHTHYRIDINE CARBOXYLIC ACID DERIVATIVE | LG CHEMICAL LTD. | 2011-12-22 | — | — | US | claimed |
| EP-1603875-B1 | NEW PROCESS FOR PREPARING 4-AMINOMETHYL-3-ALKOXYIMINOPYRROLIDINE METHANESULFONATE | LG LIFE SCIENCES LTD (KR) | 2011-09-21 | — | — | EP | claimed |
| US-20100240694-A1 | SALT OF NAPHTHYRIDINE CARBOXYLIC ACID DERIVATIVE | LG LIFE SCIENCES, LTD. | 2010-09-23 | — | — | US | claimed |
| US-7687629-B2 | Process for preparing 4-aminomethyl-3-alkoxyiminopyrrolidine methanesulfonate | LG LIFE SCIENCES LTD. (KR) | 2010-03-30 | — | — | US | claimed |
| US-20090182006-A1 | Treating a respiratory disorder by administering a hydrate of Gemifloxacinwith a carrier or excipient; chemical resistance; humidity; storage stability; thermodynamics; materials handling; sksin disorders; soft tissue-targeted therapy; sexual disorders; bovine mastitis; veterinary medicine | LG LIFE SCIENCES, LTD. | 2009-07-16 | — | — | US | claimed |
| US-6723734-B2 | GEMIFLOXACIN MESYLATE (7-(3-AMINOMETHYL-4-METHOXYIMINOPYRROLIDIN-1-YL)-1-CYCLOPROPYL-6 -FLUORO-4-OXO-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID METHANESULFONATE) AND HYDRATES THEREOF; ANTIBACTERIAL THERAPY | LG LIFE SCIENCES, LTD. (KR) | 2004-04-20 | — | — | US | claimed |
| EP-1179533-B1 | Salt of naphthyridine carboxylic acid derivative | LG LIFE SCIENCES LTD (KR) | 2004-01-14 | — | — | EP | claimed |
| EP-0981527-B1 | SALT OF NAPHTHYRIDINE CARBOXYLIC ACID DERIVATIVE | LG LIFE SCIENCES LTD (KR) | 2003-05-07 | — | — | EP | claimed |
| US-20030050321-A1 | Salt of naphthyridine carboxylic acid derivative | LG CHEMICAL LTD. | 2003-03-13 | — | — | US | claimed |
| WO-2003011450-A1 | PROCESSES FOR THE PRODUCTION OF AMINO-PROTECTED DERIVATIVES OF 4-AMINOMETHYLENE-PYRROLIDIN-3-ONE AND/OR 4-AMINOMETHYLENE-PYRROLIDIN-3-ALKOXYIMINO DERIVATIVES AND/OR GEMIFLOXACIN OR A SALT THEREOF | LG LIFE SCIENCES LIMITED (KR) | 2003-02-13 | — | — | WO | claimed |
| US-20020032216-A1 | Salt of naphthyridine carboxylic acid derivative | LG CHEMICAL LTD. | 2002-03-14 | — | — | US | claimed |
| EP-1179533-A2 | Salt of naphthyridine carboxylic acid derivative | LG CHEMICAL LIMITED (KR) | 2002-02-13 | — | — | EP | claimed |
| US-6307059-B1 | PREPARATION OF QUINOLONE ANTIBIOTICS. | LG CHEMICAL, LTD (KR) | 2001-10-23 | — | — | US | claimed |
| EP-0981527-A1 | SALT OF NAPHTHYRIDINE CARBOXYLIC ACID DERIVATIVE | LG Life Sciences Ltd. (KR) | 2000-03-01 | — | — | EP | claimed |
| WO-1998042705-A1 | SALT OF NAPHTHYRIDINE CARBOXYLIC ACID DERIVATIVE | LG CHEMICAL LTD. (KR) | 1998-10-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291585-A1 | SALT OF NAPHTHYRIDINE CARBOXYLIC ACID DERIVATIVE | NANP, NRDC, ABCB11 | LMNA 2222/4885KDM4E 3279/4885HSD17B10 3215/4885 |
| US-20090182006-A1 | Treating a respiratory disorder by administering a hydrate of Gemifloxacinwith a carrier or excipient; chemical resistance; humidity; storage stability; thermodynamics; materials handling; sksin disorders; soft tissue-targeted therapy; sexual disorders; bovine mastitis; veterinary medicine | FIS1, GSDMD, SUCNR1 | LMNA 1429/4885KDM4E 2174/4885HSD17B10 2434/4885 |
| US-20130065917-A1 | SALT OF NAPHTHYRIDINE CARBOXYLIC ACID DERIVATIVE | NANP, NRDC, ABCB11 | LMNA 2222/4885KDM4E 3279/4885HSD17B10 3215/4885 |
| US-20020032216-A1 | Salt of naphthyridine carboxylic acid derivative | NANP, NRDC, ABCB11 | LMNA 2222/4885KDM4E 3279/4885HSD17B10 3215/4885 |
| US-20160264569-A1 | SALT OF NAPHTHYRIDINE CARBOXYLIC ACID DERIVATIVE | NANP, NRDC, ABCB11 | LMNA 2222/4885KDM4E 3279/4885HSD17B10 3215/4885 |
| US-20110312987-A1 | SALT OF NAPHTHYRIDINE CARBOXYLIC ACID DERIVATIVE | NANP, NRDC, ABCB11 | LMNA 2222/4885KDM4E 3279/4885HSD17B10 3215/4885 |
| US-20100240694-A1 | SALT OF NAPHTHYRIDINE CARBOXYLIC ACID DERIVATIVE | NANP, NRDC, ABCB11 | LMNA 2222/4885KDM4E 3279/4885HSD17B10 3215/4885 |
| US-20170253588-A1 | SALT OF NAPHTHYRIDINE CARBOXYLIC ACID DERIVATIVE | NANP, NRDC, ABCB11 | LMNA 2222/4885KDM4E 3279/4885HSD17B10 3215/4885 |
| US-20030050321-A1 | Salt of naphthyridine carboxylic acid derivative | NANP, NRDC, ABCB11 | LMNA 2222/4885KDM4E 3279/4885HSD17B10 3215/4885 |
| US-20140187576-A1 | SALT OF NAPHTHYRIDINE CARBOXYLIC ACID DERIVATIVE | NANP, NRDC, ABCB11 | LMNA 2222/4885KDM4E 3279/4885HSD17B10 3215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.